What TRIUMF does

TRIUMF is Canada's national particle accelerator centre, a not-for-profit research laboratory founded in 1968 and located on the University of British Columbia campus in Vancouver. Owned by a consortium of 21 Canadian universities and governed by a Members' Council, Science Council, and Board of Governors, the laboratory operates world-unique accelerator infrastructure including the 520 MeV cyclotron (the world's largest normally conducting cyclotron, recognized by Guinness World Records), ARIEL (the world's most powerful Isotope Separation Online complex), a superconducting electron linear accelerator, and specialized facilities such as TITAN (precision mass measurement of highly charged rare isotopes), GRIFFIN (rare-isotope decay spectroscopy), and North America's only muon spin rotation (μSR) facility. TRIUMF hosts the ATLAS Tier-1 Data Centre for CERN's Large Hadron Collider and contributes to international experiments at J-PARC and SNOLAB.

TRIUMF serves three primary customer segments: (1) academic researchers across its 21 member universities and international collaborators, who access accelerator infrastructure and beam time through a formal experimenter portal at no cost when approved by Experiment Evaluation Committees; (2) healthcare providers and medical research institutions supplied with medical isotopes and radiopharmaceuticals through a commercial partnership with BWXT Medical, delivering approximately 2 million patient doses annually worldwide; and (3) aerospace, defense, and electronics companies purchasing commercial irradiation testing at the Proton Irradiation Facility (PIF) and Neutron Irradiation Facility (NIF) at hourly rates of $525–$1,200, with named customers including MDA Corporation, Boeing, and Cisco Systems. The Institute for Advanced Medical Isotopes (IAMI) on the TRIUMF campus extends the lab into next-generation radiopharmaceutical research, including novel therapeutic isotopes such as actinium-225.

Revenue is a hybrid of core federal funding through the National Research Council Canada ($399.8M announced April 2024, $1.3B announced July 2025), commercial beam-time and irradiation services, medical isotope production via the BWXT Medical channel, and technology commercialization through TRIUMF Innovations (licensing, company creation, and the AAPS commercialization subsidiary). The laboratory maintains active public engagement including Saturday Morning Lectures, public facility tours reaching over 16,500 participants annually, K-12 programs, arts and culture collaborations, and a strong social media presence. TRIUMF celebrated the 50th anniversary of its first cyclotron beam in December 2024.

Name

TRIUMF

Legal name

TRIUMF INC.

Website

https://triumf.ca

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

251–500 employees

Short description

TRIUMF is Canada's national particle accelerator centre, operating world-unique accelerator infrastructure in Vancouver since 1968 for academic research, medical isotope production (~2M patient doses/year via BWXT Medical), and commercial radiation testing for aerospace and electronics clients.

Ownership category

akta.pro rank

Product category

Particle Accelerator Research Services

NAICS

Testing Laboratories and Services (54138), Medical and Diagnostic Laboratories (6215)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Radiation Detection Instruments & Systems (Portal monitors, spectrometers, contamination monitors) (EUAKAIAK), Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis) (EUAKAIAL), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Industrial Isotope Production & Supply (Co-60, Ir-192, Cs-137, Am-241, etc.) (EUAKAIAB)

Keywords

• Particle accelerator research
• Nuclear physics research
• Medical isotope production
• Radiation testing services
• Rare isotope production

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Others

Revenue model

1. Government Funding: TRIUMF receives core operational funding primarily from the federal government through the National Research Council Canada (NRC). The 2024 federal investment of $399.8M and the 2025 $1.3B announcement represent major funding commitments for Canadian science infrastructure.
2. Medical Isotope Production: Commercial production and distribution of medical isotopes through partnership with BWXT Medical, delivering approximately 2 million patient doses annually for diagnostic scans worldwide
3. Irradiation Services (PIF & NIF): Proton and neutron irradiation facilities providing radiation testing services to aerospace, defense, and electronics companies. Beam time is sold at hourly rates ($525-$1200/hour depending on beamline and user origin)
4. Technology Commercialization: Revenue generated through TRIUMF Innovations via licensing, company creation, and industry partnerships leveraging made-at-TRIUMF technologies in mining, medical imaging, and other industries
5. Beam Time Sales: Academic researchers receive free access when approved by Experiment Evaluation Committees, while commercial and some research users purchase beam time for specialized experiments and testing

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

TRIUMF operates Canada's national particle accelerator centre, providing access to world-unique accelerator infrastructure for subatomic physics research, rare isotope beam production, and medical isotope manufacturing. The laboratory offers paid beam time access at hourly rates for commercial irradiation testing of aerospace and electronics components, produces medical isotopes distributed globally through BWXT Medical, and provides radiopharmaceutical research and production services for healthcare institutions.

Product overview

TRIUMF is Canada's national particle accelerator centre located in Vancouver, British Columbia, established in 1968. As a not-for-profit research laboratory owned by a consortium of 21 Canadian universities, TRIUMF does not offer commercial software products or services in the traditional sense. Instead, it provides access to world-class accelerator infrastructure and scientific facilities for research purposes. These include the 520 MeV cyclotron (the world's largest normally-conducting cyclotron), the Advanced Rare Isotope Laboratory (ARIEL), the Institute for Advanced Medical Isotopes (IAMI), various experimental facilities (ISAC, GRIFFIN, TITAN, TIGRESS, DRAGON), medical isotope production facilities (ATG Facilities, TR-13 and TR-24 cyclotrons), and irradiation facilities (PIF & NIF) for radiation testing. TRIUMF also offers beam time access, technical consulting, professional training, and irradiation services to qualified researchers and industry partners.

Differentiator

Problem solved

Functional benefit

Products and services

• Proton and Neutron Irradiation Services (PIF & NIF) Radiation testing services using TRIUMF's Proton Irradiation Facility (PIF) and Neutron Irradiation Facility (NIF). Beam time is sold at hourly rates ranging from $525 to $1200 per hour depending on beamline and user origin, with minimum 6-hour bookings. Customers include MDA Corporation, Boeing, and Cisco Systems for space, avionics, and microelectronics radiation qualification.
• Medical Isotope Production Commercial production of medical isotopes for diagnostic imaging (PET scans) and therapeutic applications including novel isotopes like actinium-225. Approximately 2 million patient doses delivered annually worldwide through the BWXT Medical distribution partnership.
• Radiopharmaceutical Production and Supply Development and supply of radiopharmaceuticals and radiotracers for PET imaging and pre-clinical studies. Direct supply to BC Cancer, UBC PET/MRI Imaging Centre, and Djavad Mowafaghian Centre for Brain Health for research and clinical applications including brain imaging studies for Parkinson's and Alzheimer's disease.
• Commercial Beam Time Access Access to TRIUMF's particle accelerator infrastructure and rare isotope beams for specialized experiments. Academic researchers receive free access when approved by Experiment Evaluation Committees, while commercial and some research users purchase beam time through the Experimenter Portal for specialized experiments and component testing.
• Technology Commercialization and Licensing (via TRIUMF Innovations) Revenue generation through TRIUMF Innovations via licensing, company creation, and industry partnerships leveraging made-at-TRIUMF technologies in mining, medical imaging, and other industries. Supports the Canadian Medical Isotope Ecosystem (CMIE).

Quantifiable outcome

• 2 million patient doses of medical isotopes delivered annually worldwide through BWXT Medical partnership
• +4 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• 21 Canadian Member UniversitiescoreStrategic or Co-development Partner · 1 January 1968TRIUMF was founded as a consortium of Canadian universities to provide centralized resources and expertise in subatomic physics. Member universities span from Victoria to Halifax and include University of British Columbia, Simon Fraser University, University of Toronto, McGill University, and others. Universities provide governance oversight through the Members' Council and Science Council, and enable researchers to access TRIUMF facilities.
• BWXT MedicalcoreStrategic or Co-development PartnerCommercial partnership for medical isotope production and distribution. TRIUMF produces medical isotopes using its cyclotron facilities, with BWXT Medical handling commercial distribution. Approximately 2 million patient doses of medical isotopes are delivered annually worldwide through this partnership.
• CERN (European Organization for Nuclear Research)coreStrategic or Co-development PartnerTRIUMF serves as Canada's gateway to global particle physics through its partnership with CERN. Canadian scientists participate in the ATLAS experiment at the Large Hadron Collider, which led to the Nobel Prize-winning discovery of the Higgs boson. TRIUMF hosts the ATLAS Tier-1 Data Centre and contributes to the High-Luminosity LHC upgrade.
• J-PARC (Japan Proton Accelerator Research Complex)coreStrategic or Co-development PartnerTRIUMF leads Canada's contribution to the T2K (Tokai to Kamioka) long-baseline neutrino experiment and the upcoming Hyper-Kamiokande experiment at J-PARC in Japan. These experiments study neutrino properties and matter-antimatter asymmetry.
• SNOLABcoreStrategic or Co-development PartnerTRIUMF collaborates with SNOLAB on dark matter experiments including SuperCDMS and nEXO. SNOLAB is a world-class underground laboratory located in Sudbury, Ontario, specializing in neutrino and dark matter physics.
• TRIUMF InnovationscoreStrategic or Co-development PartnerTRIUMF's commercialization arm responsible for technology transfer, licensing, and company creation. Supports the development of the Canadian Medical Isotope Ecosystem (CMIE) and has helped create spin-off companies using TRIUMF-developed technologies for mining, medical imaging, and other industries.
• Advanced Applied Physics Solutions (AAPS)minorStrategic or Co-development PartnerA wholly-owned not-for-profit subsidiary of TRIUMF established in 2008 as one of 11 Centres of Excellence for Commercialization and Research (CECRs). Received $14.95M over five years from the Canadian government to facilitate bringing major scientific discoveries to the marketplace.
• National Research Council Canada (NRC)coreStrategic or Co-development PartnerNRC oversees the Government of Canada's investment in TRIUMF through the Agency Committee on TRIUMF (ACT). NRC also provides oversight via the Advisory Committee on TRIUMF (ACOT) which advises on all aspects of TRIUMF's program relating to federal government contributions.
• University of British Columbia (UBC)coreStrategic or Co-development PartnerTRIUMF is located on UBC's campus and maintains deep collaborations including the PET/MRI Imaging Center, joint research programs, and shared facilities. Many TRIUMF scientists hold joint appointments with UBC.
• BC CancercoreStrategic or Co-development PartnerLong-standing collaboration for radiopharmaceutical research and development. TRIUMF provides various radiotracers for animal and pre-clinical studies at BC Cancer. Joint work on therapeutic radiopharmaceuticals using novel isotopes for cancer treatment.
• RADNEXT ConsortiumminorStrategic or Co-development PartnerTRIUMF is a partner facility in RADNEXT, an H2020 INFRAIA European infrastructure project creating a network of irradiation facilities for electronics component and system testing. The network responds to emerging needs for radiation testing across industries.
• Institute for Advanced Medical Isotopes (IAMI)coreStrategic or Co-development PartnerIAMI is a state-of-the-art life sciences research centre established on the TRIUMF campus for research into next-generation medical isotopes and radiopharmaceuticals. Will significantly increase BC and Canada's capacity for radiopharmaceutical research and production.

Scale indicators15 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Brookhaven National Laboratory: US Department of Energy national laboratory operating particle accelerators (RHIC, NSRL) and conducting nuclear physics, isotope production, and radiation testing research. Directly comparable as a government-funded multidisciplinary accelerator lab with similar commercial beam time offerings and medical isotope production.
• Argonne National Laboratory: US DOE lab with the Advanced Photon Source and ATLAS accelerator, conducting nuclear physics, materials science, and life sciences research with major federal backing. Comparable scale and mission to TRIUMF as a multi-program national laboratory with accelerator-based science.
• Fermi National Accelerator Laboratory (Fermilab): US DOE flagship particle physics laboratory operating high-energy accelerators (Tevatron legacy, PIP-II upgrade) with international collaborations. Comparable in scale, federal funding model, and focus on particle/nuclear physics research and accelerator technology development.
• Oak Ridge National Laboratory (ORNL): US DOE multiprogram science lab operating the Spallation Neutron Source and High Flux Isotope Reactor for neutron science, isotope production, and materials research. Comparable in neutron irradiation services for industry, medical isotope production, and federally funded multiprogram research scale.
• SLAC National Accelerator Laboratory: Stanford-affiliated DOE lab operating linear accelerators for particle physics, photon science, and accelerator technology R&D. Comparable as a government-funded accelerator facility with strong university ties and broad scientific program spanning physics and applied research.

Direct peers

• Facility for Rare Isotope Beams (FRIB) at Michigan State University: US DOE user facility dedicated to rare isotope research, with the world's most powerful superconducting linear accelerator for isotope production. Direct competitor in rare isotope science and likely beneficiary of similar federal research funding dynamics; most direct functional parallel to TRIUMF's ARIEL program.
• Paul Scherrer Institute (PSI): Swiss national laboratory operating a high-power cyclotron for proton therapy, isotope production, and muon spin rotation (μSR) research. Direct competitor in μSR (one of only ~4 worldwide), medical isotope production, and proton irradiation services for industry.
• RIKEN Nishina Center for Accelerator-Based Science: Japanese national laboratory operating heavy-ion accelerators (including RIBF) for rare isotope research and nuclear physics. Direct peer in rare isotope production and accelerator-based nuclear science with similar government-backed international collaboration model.
• GANIL (Grand Accélérateur National d'Ions Lourds): French national heavy-ion accelerator facility for nuclear physics and rare isotope research, with SPIRAL2 upgrade. Direct European peer in rare isotope beam production and accelerator-based nuclear science serving an international user community.

Regional players

• BWXT Medical: Commercial medical isotope manufacturer and TRIUMF's distribution partner for radiopharmaceuticals globally. Comparable as a medical isotope producer with regulatory expertise (Health Canada GMP, FDA, CNSC), serving as the commercial counterpart that translates TRIUMF's isotope production into hospital supply.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/triumflab
• Facebookfacebook.com/TRIUMFLab
• LinkedInlinkedin.com/company/triumf
• Instagraminstagram.com/triumflab
• Xx.com/triumflab

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRIUMF